MU
Michael Ulz Morgan Stanley Latest Price Targets & Analyst Ratings
Main Sector
Healthcare
Ratings Past Year
27
Avg Return
Past Year
Past Year
40%
Success Rate
Past Year
Past Year
0
%
Rating Distribution
Past Year
Positive
61.9%
Neutral
38.1%
Negative
0%
Past Week
Past Month
Past 3 Months
Past 6 Months
Past Year
All Time
Positive
Neutral
Negative
Large Cap
$10B to $200B
Mid Cap
$2B to $10B
Small Cap
$250M to $2B
Micro Cap
Under $250M
Healthcare
Healthcare
Biotechnology
Drug Manufacturers - General
| Stock | Rating | Price Target |
Upside Downside |
Ratings 1 Year |
Avg Return 1 Year |
Success Rate 1 Year | Date | |
|---|---|---|---|---|---|---|---|---|
|
Overweight
Maintained
| $47 |
151%
upside
| 2 | -6.3% |
0
%
| 3 Mar ‘26 3 months ago |
|
|
|
Equal-Weight
Downgraded
| $7 |
82%
upside
| 1 | +23% |
–
| 2 Mar ‘26 3 months ago |
|
|
|
Equal-Weight
Downgraded
| $2 |
135%
upside
| 1 | -68% |
–
| 30 Jan ‘26 4 months ago |
|
|
|
Overweight
Maintained
| $123 |
22%
upside
| 3 | +10% |
0
%
| 30 Jan ‘26 4 months ago |
|
|
|
Equal-Weight
Maintained
| $408 |
42%
upside
| 4 | – |
–
| 30 Jan ‘26 4 months ago |
|
|
|
Equal-Weight
Maintained
| $81 |
5%
upside
| 3 | – |
–
| 7 Jan ‘26 5 months ago |
|
|
|
Overweight
Maintained
| $25 |
207%
upside
| 2 | +150% |
0
%
| 4 Dec ‘25 6 months ago |
|
|
|
Overweight
Maintained
| $94 |
27%
upside
| 4 | +15% |
0
%
| 30 Oct ‘25 7 months ago |
|
|
|
Overweight
Maintained
| $102 |
244%
upside
| 2 | +18% |
0
%
| 23 Oct ‘25 7 months ago |
|
|
|
Outperform
Maintained
| $21 |
118%
upside
| 3 | +21% |
0
%
| 9 Oct ‘25 8 months ago |
|